Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations to enhance public medication safety, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's decision is based on the evaluation of adverse drug reactions, aiming to ensure safer medication use among the public [1] - The revised warning will include reports of neuropsychiatric adverse reactions across all age groups, including severe reactions such as depression and suicidal tendencies [1] Group 2: Patient Guidance - The new instructions recommend that if neuropsychiatric symptoms occur during treatment with Montelukast, the medication should be discontinued and medical attention sought [1] - Patients and caregivers are advised to be vigilant for neuropsychiatric adverse reactions and to inform healthcare providers if related symptoms arise during the medication period [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's announcement includes a warning that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [1] - It is advised that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1] - The revision also mandates the addition of stuttering as a reported adverse reaction based on post-marketing experience [1] Group 2: Expert Opinions - Ji Lianmei, founder of "Ask the Pharmacist," stated that Montelukast is not the first-line treatment for allergic rhinitis and asthma [1] - The incidence of psychiatric side effects, such as irritability and attention abnormalities, is reportedly higher in children [1] - It is emphasized that both adults and children should discontinue the medication and seek medical help if any neuropsychiatric symptoms arise, and a thorough assessment of benefits versus risks should be conducted before use [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's announcement includes a warning that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [1] - It is advised that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1] Group 2: Expert Opinions - Ji Lianmei, founder of "Ask the Pharmacist," stated that Montelukast sodium is not the first-choice medication for allergic rhinitis or asthma treatment [1] - The incidence of psychiatric side effects, such as irritability and attention abnormalities, is reportedly higher in children [1] - A thorough assessment of benefits versus risks is recommended before using the medication, and immediate discontinuation and medical consultation are advised if neuropsychiatric symptoms arise during treatment [1]

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received a change in its drug production license, extending the contract manufacturing period for Montelukast Sodium Granules until March 2, 2026, which is expected to enhance the company's production capacity utilization [1][3]. Group 1: License Change Details - The change involves the extension of the contract manufacturing period for Montelukast Sodium Granules, a product commissioned by Youhua Pharmaceutical Technology Co., Ltd. [1]. - The new drug production license number is 渝20150018, issued by the Chongqing Drug Administration [1]. Group 2: Product Information - Montelukast Sodium Granules are indicated for the prevention and long-term treatment of asthma in children over one year old, as well as for alleviating symptoms of allergic rhinitis in children aged 2 to 5 [2]. - The product is classified as a national medical insurance category B product and is recommended in several authoritative clinical guidelines, highlighting its significant market presence and advantages in pediatric formulations [2]. Group 3: Market Performance - The overall market for Montelukast Sodium has reached maturity, but the granule formulation for children continues to show strong growth potential [2]. - In the past five years (2020-2024), the cumulative sales of Montelukast Sodium formulations in domestic hospital terminals have reached 5.545 billion yuan [2]. Group 4: Impact on the Company - The change in the drug production license is expected to improve the company's production capacity utilization, although it will not have a significant short-term impact on the company's performance [3].